Split History
ETFs Holding NAVB »    NAVB Historical Stock Prices »
Video: What is a Stock Split?

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Navidea Biopharmaceuticals is a biopharmaceutical company. Co. develops several precision-targeted products based on its Manocept™ platform to help identify the sites and pathways of undetected disease. The Manocept platform serves as the molecular backbone of Lymphoseek® (technetium Tc 99m tilmanocept) injection, the product developed by Co. based on the platform. The Manocept platform acts as an engine for the design of purpose-built molecules providing the potential to be utilized in a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography, intra-operative and/or optical-fluorescence detection in a variety of disease states. According to our NAVB split history records, Navidea Biopharmaceuticals has had 1 split.
NAVB split history picture
Navidea Biopharmaceuticals (NAVB) has 1 split in our NAVB split history database. The split for NAVB took place on April 26, 2019. This was a 1 for 20 reverse split, meaning for each 20 shares of NAVB owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 50 share position following the split.

When a company such as Navidea Biopharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share. Looking at the NAVB split history from start to finish, an original position size of 1000 shares would have turned into 50 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Navidea Biopharmaceuticals shares, starting with a $10,000 purchase of NAVB, presented on a split-history-adjusted basis factoring in the complete NAVB split history. NAVB split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 07/20/2009
End date: 07/19/2019
Start price/share: $19.80
End price/share: $0.59
Dividends collected/share: $0.00
Total return: -97.02%
Average Annual Total Return: -29.62%
Starting investment: $10,000.00
Ending investment: $297.90
Years: 10.00
Date Ratio
04/26/20191 for 20
NAVB is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

NBS Split History
NBY Split History
NEOG Split History
NRCIB Split History
NSPH Split History
NSPR Split History
NURO Split History
NVAX Split History
NVGN Split History
NVIV Split History

Neuralstem, Inc. (CUR)
Francesca's Holdings Corporation (FRAN)
China Green Agriculture, Inc. (CGA)
Xenetic Biosciences, Inc. (XBIO)
Yuma Energy, Inc. (YUMA)
Avinger, Inc. (AVGR)
Sonoma Pharmaceuticals, Inc. (SOMA)
Hudson Global, Inc. (HSON)
Jaguar Health, Inc. (JAGX)
Cesca Therapeutics Inc. (KOOL)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

NAVB Insider Buying

NAVB Split History | www.SplitHistory.com | Copyright © 2013 - 2019, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.